Seminars in Oncology
Volume 37, Issue 3 , Pages 224-242 , June 2010

Molecular Markers for Early Detection

  • Barbara K. Dunn

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, MD
    • Corresponding Author InformationAddress correspondence to Barbara K. Dunn, MD, PhD, Medical Officer, Basic Prevention Science Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Room 2056, Bethesda, MD 20892-7340
    • ,
  • Paul D. Wagner

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, MD
    • ,
  • Darrell Anderson

      Affiliations

    • Scientific Consulting Group, Gaithersburg, MD
    • ,
  • Peter Greenwald

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, MD

References 

  1. Greenwald P, Dunn BK. Landmarks in the history of cancer epidemiology. Cancer Res. 2009;69:2151–2162
  2. Society of Actuaries. Joint Committee of the Actuarial Society of America and the Association of Life Insurance Medical Directors. Blood pressure. Report 1-54. New York, NY 1925;
  3. Dustan HP. 50th anniversary historical article (Hypertension). J Am Coll Cardiol. 1999;33:595–597
  4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  5. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. Am Assoc Pharmaceut Sci J. 2006;8:E146–E152
  6. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061
  7. National Cancer Institute. Division of Cancer Prevention. The Early Detection Research Network: translational research to identify early cancer and cancer risk. Initial report October 2000. 1-44. 2000. National Cancer Institute, Division of Cancer Prevention. 3-4-2010.
  8. Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr. 2002;132:2471S–2475S
  9. Cancer Biomarkers Research Group. EDRN Fourth Report: Investing in translational research on biomarkers of early cancer and cancer risk. NIH Publication No. 07-6135 In: Bethesda, MD: National Institutes of Health, National Cancer Institute; 2008;p. 1–126http://edrn.nci.nih.gov/docs/progress-reports/edrn_4th-report_200801.pdfAccessed February 26, 2010
  10. Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26–38
  11. Fabian CJ, Kimler BF. Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol. 2007;106:31–39
  12. Pritzker KP. Cancer biomarkers: easier said than done. Clin Chem. 2002;48:1147–1150
  13. Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res. 2007;67:5600–5605
  14. Grunau C, Brun ME, Rivals I, et al. BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection. Cancer Epidemiol Biomarkers Prev. 2008;17:1374–1379
  15. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29:181–206
  16. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–450W81
  17. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97:1124–1132
  18. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–118
  19. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502
  20. Sun Y, Mi W, Cai J, et al. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008;7:3847–3859
  21. Akagi T, Ito T, Kato M, et al. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer. 2009;125:2349–2359
  22. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–5327
  23. Lott ST, Chen N, Chandler DS, et al. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009;6:e1000068
  24. Irminger-Finger I. BARD1, a possible biomarker for breast and ovarian cancer. Gynecol Oncol. 2010;117:211–215
  25. Wang W, Srivastava S. Strategic approach to validating methylated genes as biomarkers for breast cancer. Cancer Prev Res. 2010;3:16–24
  26. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004;64:4442–4452
  27. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev. 2009;18:1365–1372
  28. Stacey SN, Sulem P, Johannsson OT, et al. The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med. 2006;3:e217
  29. Rebbeck TR, Mitra N, Domchek SM, et al. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009;69:5801–5810
  30. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–359
  31. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109–118
  32. Park HS, Park WS, Bondaruk J, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008;100:1401–1411
  33. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26:5060–5066
  34. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006;66:3338–3344
  35. Han W, Wang T, Reilly AA, Keller SM, Spivack SD. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir Res. 2009;10:86
  36. Tezval H, Merseburger AS, Matuschek I, Machtens S, Kuczyk MA, Serth J. RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma. BMC Urol. 2008;8:12
  37. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43:415–432
  38. Calmon MF, Rodrigues RV, Kaneto CM, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11:1329–1339
  39. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27:2450–2456
  40. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951–1960
  41. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  42. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326:1230
  43. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706–4711
  44. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645–649
  45. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  46. Ruault M, van der Bruggen P, Brun ME, Boyle S, Roizes G, De SA. New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur J Hum Genet. 2002;10:833–840
  47. Grunau C, Sanchez C, Ehrlich M, et al. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer. 2005;43:11–24
  48. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111–117
  49. Gomes AJ, Roy HK, Turzhitsky V, et al. Rectal mucosal microvascular blood supply increase is associated with colonic neoplasia. Clin Cancer Res. 2009;15:3110–3117
  50. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008;7:4004–4012
  51. Mehta A, Block TM. Fucosylated glycoproteins as markers of liver disease. Dis Markers. 2008;25:259–265
  52. Goldman R, Ressom HW, Abdel-Hamid M, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007;28:2149–2153
  53. Goldman R, Ressom HW, Varghese RS, et al. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808–1813
  54. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009;69:4112–4115
  55. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67
  56. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182–186
  57. Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008;5:e123
  58. Zeh HJ, Winikoff S, Landsittel DP, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 2005;1:259–269
  59. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010;70:1306–1313
  60. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics. 2009;8:1697–1707
  61. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer. 2005;12:185–213
  62. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res. 2006;12:3661–3697
  63. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–340
  64. Agency for Healthcare Research and Quality. Evaluation of cervical cytology (Summary, evidence report/technology assessment: number 5). Rockville, MD: Agency for Health Care Policy and Research, Rockville, MD; January 1999;http://www.ahrq.gov/clinic/epcsums/cervsumm.htmAccessed February 26, 2010
  65. Stephenson M, Doughty C. Performance of commercially available HPV tests. NZHTA Technical Brief. 2007;6:1–64
  66. Balasubramanian A, Hughes J, Mao C, et al. Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3008–3017
  67. Brown FM. Urine cytology (It is still the gold standard for screening?). Urol Clin North Am. 2000;27:25–37
  68. US Food and Drug Administration. Premarket approval of Matritech Inc (Matritech NMP22 test kit). http://www.accessdata.fda.gov/cdrh_docs/pdf/p940035. pdfAccessed March 16, 2010
  69. Chiong E, Gaston KE, Grossman HB. Urinary markers in screening patients with hematuria. World J Urol. 2008;26:25–30
  70. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 1999;161:62–65
  71. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2010;183:62–67
  72. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 1997;3:621–624
  73. Lin DW. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol. 2009;27:315–321
  74. Troyer DA, Lucia MS, de Bruine AP, et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev. 2009;18:2717–2722
  75. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004;165:1543–1556
  76. Canary Foundation. Prostate Active Surveillance Study (PASS). Stanford, CA: Canary Foundation; 2010;http://www.canaryfoundation.org/prostate-clinical-studies.cfmAccessed March 10, 2010
  77. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51:1244–1250
  78. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 2004;10:2284–2288
  79. Horvath I, Lazar Z, Gyulai N, Kollai M, Losonczy G. Exhaled biomarkers in lung cancer. Eur Respir J. 2009;34:261–275
  80. Drake RR, Cazare LH, Semmes OJ, Wadsworth JT. Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. Expert Rev Mol Diagn. 2005;5:93–100
  81. Chang SS, Califano J. Current status of biomarkers in head and neck cancer. J Surg Oncol. 2008;97:640–643
  82. Ramachandran N, Raphael JV, Hainsworth E, et al. Next-generation high-density self-assembling functional protein arrays. Nat Methods. 2008;5:535–538
  83. Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008;7:1490–1499
  84. Harinck F, Poley JW, Kluijt I, et al. Comparative yield of endosonography and magnetic resonance imaging in individuals at high-risk for pancreatic cancer. Gastroenterology. 2009;136:A147
  85. Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics. 2005;5:2602–2611
  86. Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol. 2008;61:49–58
  87. Sitek B, Sipos B, Alkatout I, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res. 2009;8:1647–1656

PII: S0093-7754(10)00072-2

doi: 10.1053/j.seminoncol.2010.05.007

Seminars in Oncology
Volume 37, Issue 3 , Pages 224-242 , June 2010

Article Tools

* Image Usage & Resolution